•  
  •  
  •  
  •  

2025-09-30 04:48:01

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark

Keywords Selected:  DrReddysLaboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for AVT03 - denosumab
  • Dr. Reddy's launches novel molecule 'Tegoprazan' in India
  • Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda®
  • USFDA completes GMP inspection at Dr. Reddy's Laboratories Ltd's API Middleburgh facility
  • Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy's Laboratories
  • Dr. Reddy’s Laboratories Ltd Q3 FY2025 consolidated PAT higher at Rs. 1413.3 crores
  • Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
  • IPO-bound Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
  • Dr. Reddy's Laboratories Ltd reports Rs. 1255.3 crores consolidated PAT in Q2 FY2025
  • Aurigene Oncology Ltd announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma
  • Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
  • Dr. Reddy's Laboratories Ltd receives order from COFEPRIS
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
  • Dr Reddys Laboratories Ltd reports Rs. 1392 crores consolidated PAT in Q1FY25
  • Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan
  • Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
  • Dr. Reddy's to acquire Nicotinell and related portfolio
  • LIC increases stake in Dr. Reddys Laboratories Ltd
  • Dr. Reddy's Laboratories Limited gets Form 483 from USFDA with 4 observations for API facility
  • Aurigene Pharmaceutical Services Ltd opens biologics facility in Genome Valley, Hyderabad
  • Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 40
  • Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S.
  • Nestlé India and Dr. Reddy's to form joint venture to take health science nutraceutical portfolio to consumers across India and other agreed territories
  • Dr. Reddy's launches Condition Management programme 'DailyBloom™ IBS'

Latest Post

  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024